Oncology Times - OncTimes Talk

What's Oncology Times - OncTimes Talk about?

Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!

Download our free app to listen on your phone

Oncology Times - OncTimes Talk episodes:

04.15.2024
Artificial Intelligence Tool Predicts Postoperative Radiotherapy Lymphedema
04.15.2024
Neoadjuvant Pembrolizumab Improves High-Risk Early Breast Cancer Outcomes
04.12.2024
Preoperative Partial Breast Irradiation: Marked Benefit in Low-Risk Breast Cancer
04.11.2024
Adjuvant Atezolizumab: No Survival Benefit in Triple-Negative Breast Cancer
03.27.2024
Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab
03.22.2024
Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia
03.12.2024
Important Mantle Cell Lymphoma Findings From the Sympatico Study
03.06.2024
World’s Largest Prostate Cancer Trial, STAMPEDE, Celebrates 20 Years of Progress
03.04.2024
Doublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC Progression
02.29.2024
Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias
02.28.2024
INTERLACE Study Boosts Cervical Cancer Survival
02.16.2024
RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients
02.16.2024
Afatinib Recommended for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations
02.14.2024
Adjuvant Radiotherapy No Benefit After Radical Prostatectomy
02.14.2024
Collagen-Bound Interleukin 12 Converts “Cold” Tumors Into “Hot” Ones
02.07.2024
Allogeneic Transplant for AML: Only in Patients Negative for Molecular Minimum Residual Disease
02.05.2024
Antibody-Drug Conjugate Brings Success in High-Risk R/R Follicular Lymphoma
01.17.2024
Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL
$Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL$
01.17.2024
Relapsed or Refractory CLL - With Sameer A. Parikh, MBBS, and Alessandra Ferrajoli, MD
$Relapsed or Refractory CLL - With Sameer A. Parikh, MBBS, and Alessandra Ferrajoli, MD$
01.16.2024
CLL Frontline Treatment - With Sameer A. Parikh, MBBS, & Alessandra Ferrajoli, MD
11.30.2023
Sabestomig in Non-Small Cell Lung Cancer: Bi-Specific Antibody Safe and Active
11.22.2023
Radicals Study Finds Adjuvant Radiotherapy No Benefit After Radical Prostatectomy
11.16.2023
Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition
$Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition$
11.16.2023
Collagen-Bound Interleukin 12 Converts “Cold” Tumors into “Hot” Ones
11.16.2023
Double TKI Therapy Improves Responses in MET Amplification-Driven EGFR-Mutant Non-Small Cell Lung Cancer
11.15.2023
CLIC Protein Inhibition Key to Metformin’s Anti-Neoplastic Properties
11.14.2023
Adjuvant ATR Inhibition Prolonged Life in Patients with Relapsed Small Cell Lung Cancer
11.13.2023
Mitophagy Discovered as Potential Reason for AML’s Resistance to Venetoclax
08.31.2023
Unintentional Bias of Breast Cancer Randomized Clinical Trial Interpretations Through Discontinuation Imbalance
08.22.2023
Trastuzumab Deruxtecan Benefits Patients with HER2-Low Metastatic Breast Cancer Irrespective of ER Expression
08.18.2023
Artificial Intelligence Model Predicts Overall Survival in Patients with Metastatic Breast Cancer
08.10.2023
Axillary Dissection in Older Women With Clinically Node-Negative Breast Cancer
08.07.2023
Variability of Biological Parameters Between Tumor Biopsy & Surgical Samples in Breast Cancer Patients
07.25.2023
Full Compliance With Adjuvant Endocrine Therapy Brings 15 Percent Superior Survival in Patients With Breast Cancer
07.17.2023
Being Obese & Overweight Reduces Efficacy of Extended Endocrine Therapy in HR+ Breast Cancer
06.30.2023
ASCO 2023: Neoadjuvant Pembrolizumab Brought Big Benefit in Early-Stage Non-Small Cell Lung Cancer with Heather A. Wakelee, MD, FASCO
06.28.2023
ASCO 2023: How AI Can Help Physicians Communicate with Dying Patients Better & Also Reduce Costs
06.26.2023
Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD
06.22.2023
Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD
05.12.2023
Emerging Cancer Treatments for Esophageal Cancer with Brian Henick, MD
04.12.2023
Meet the New Oncology Times Editorial Board Chair: Stephanie L. Graff, MD, FACP
03.15.2023
Ravi B. Parikh, MD, on How Machine Learning-Triggered Reminders Can Improve End-of-Life Care for Cancer Patients
02.22.2023
Deanna Gerber, MD, on Navigating Cervical Cancer Screening
01.27.2023
January Research Review: Promising Results in HemOnc Clinical Trials
12.22.2022
Unraveling a Complex Disease: Gary K. Schwartz, MD, on Sarcoma Research Highlights, Targeted Agents & Future Directions
12.20.2022
ASH 2022: David Sallman, MD, Discusses Positive Phase I Dose Escalation Data for PRGN-3006 UltraCAR-T in AML Patients
11.23.2022
Anil K. Rustgi, MD, on the Current State of Colorectal Cancer Screening
11.15.2022
Small Bytes: Phase I Study Finds Pan-AKT Inhibitor Ipatasertib Safe & Effective, Featuring Carolyn McCourt, MD
11.15.2022
Small Bytes: How ctDNA Liquid Biopsies Can Detect Myeloid Malignancies & Occult Tumors
10.28.2022
Dr. Lisa Newman on Eliminating Racial Disparities in Breast Cancer

What's Oncology Times - OncTimes Talk about?

Download our free app to listen on your phone

Oncology Times - OncTimes Talk episodes:

Artificial Intelligence Tool Predicts Postoperative Radiotherapy Lymphedema

Neoadjuvant Pembrolizumab Improves High-Risk Early Breast Cancer Outcomes

Preoperative Partial Breast Irradiation: Marked Benefit in Low-Risk Breast Cancer

Adjuvant Atezolizumab: No Survival Benefit in Triple-Negative Breast Cancer

Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab

Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia

Important Mantle Cell Lymphoma Findings From the Sympatico Study

World’s Largest Prostate Cancer Trial, STAMPEDE, Celebrates 20 Years of Progress

Doublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC Progression

Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias

INTERLACE Study Boosts Cervical Cancer Survival

RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients

Afatinib Recommended for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations

Adjuvant Radiotherapy No Benefit After Radical Prostatectomy

Collagen-Bound Interleukin 12 Converts “Cold” Tumors Into “Hot” Ones

Allogeneic Transplant for AML: Only in Patients Negative for Molecular Minimum Residual Disease

Antibody-Drug Conjugate Brings Success in High-Risk R/R Follicular Lymphoma

Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL

Relapsed or Refractory CLL - With Sameer A. Parikh, MBBS, and Alessandra Ferrajoli, MD

CLL Frontline Treatment - With Sameer A. Parikh, MBBS, & Alessandra Ferrajoli, MD

Sabestomig in Non-Small Cell Lung Cancer: Bi-Specific Antibody Safe and Active

Radicals Study Finds Adjuvant Radiotherapy No Benefit After Radical Prostatectomy

Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition

Collagen-Bound Interleukin 12 Converts “Cold” Tumors into “Hot” Ones

Double TKI Therapy Improves Responses in MET Amplification-Driven EGFR-Mutant Non-Small Cell Lung Cancer

CLIC Protein Inhibition Key to Metformin’s Anti-Neoplastic Properties

Adjuvant ATR Inhibition Prolonged Life in Patients with Relapsed Small Cell Lung Cancer

Mitophagy Discovered as Potential Reason for AML’s Resistance to Venetoclax

Unintentional Bias of Breast Cancer Randomized Clinical Trial Interpretations Through Discontinuation Imbalance

Trastuzumab Deruxtecan Benefits Patients with HER2-Low Metastatic Breast Cancer Irrespective of ER Expression

Artificial Intelligence Model Predicts Overall Survival in Patients with Metastatic Breast Cancer

Axillary Dissection in Older Women With Clinically Node-Negative Breast Cancer

Variability of Biological Parameters Between Tumor Biopsy & Surgical Samples in Breast Cancer Patients

Full Compliance With Adjuvant Endocrine Therapy Brings 15 Percent Superior Survival in Patients With Breast Cancer

Being Obese & Overweight Reduces Efficacy of Extended Endocrine Therapy in HR+ Breast Cancer

ASCO 2023: Neoadjuvant Pembrolizumab Brought Big Benefit in Early-Stage Non-Small Cell Lung Cancer with Heather A. Wakelee, MD, FASCO

ASCO 2023: How AI Can Help Physicians Communicate with Dying Patients Better & Also Reduce Costs

Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD

Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD

Emerging Cancer Treatments for Esophageal Cancer with Brian Henick, MD

Meet the New Oncology Times Editorial Board Chair: Stephanie L. Graff, MD, FACP

Ravi B. Parikh, MD, on How Machine Learning-Triggered Reminders Can Improve End-of-Life Care for Cancer Patients

Deanna Gerber, MD, on Navigating Cervical Cancer Screening

January Research Review: Promising Results in HemOnc Clinical Trials

Unraveling a Complex Disease: Gary K. Schwartz, MD, on Sarcoma Research Highlights, Targeted Agents & Future Directions

ASH 2022: David Sallman, MD, Discusses Positive Phase I Dose Escalation Data for PRGN-3006 UltraCAR-T in AML Patients

Anil K. Rustgi, MD, on the Current State of Colorectal Cancer Screening

Small Bytes: Phase I Study Finds Pan-AKT Inhibitor Ipatasertib Safe & Effective, Featuring Carolyn McCourt, MD

Small Bytes: How ctDNA Liquid Biopsies Can Detect Myeloid Malignancies & Occult Tumors

Dr. Lisa Newman on Eliminating Racial Disparities in Breast Cancer